Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome

Trial Profile

Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Miransertib (Primary)
  • Indications Proteus syndrome
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 09 Nov 2017 Preliminary data presented at the Proteus Syndrome Foundation Family Conference in September 2017, according to an ArQule, Inc. media release.
    • 20 Jan 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
    • 20 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top